Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,874
edits
Changes
HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (view source)
Revision as of 14:25, 13 December 2023
, 14:25, 13 December 2023no edit summary
{{Under Construction}}
{{Under Construction}}
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]].
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]].
}}</blockquote>
}}</blockquote>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
==Primary Author(s)*==
==Primary Author(s)*==
__TOC__
__TOC__
==Cancer Category/Type==
==Cancer Category / Type==
[[Mature B cell neoplasm]]
[[Mature B cell neoplasm]]
*7-8% of all B cell lymphoma <ref>{{Cite journal|last=Kuper-Hommel|first=Marion J. J.|last2=van de Schans|first2=Saskia A. M.|last3=Vreugdenhil|first3=Gerard|last4=van Krieken|first4=J. Han J. M.|last5=Coebergh|first5=Jan Willem W.|date=2013-09|title=Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites|url=https://pubmed.ncbi.nlm.nih.gov/23302044|journal=Leukemia & Lymphoma|volume=54|issue=9|pages=1891–1897|doi=10.3109/10428194.2013.764421|issn=1029-2403|pmid=23302044}}</ref>
*7-8% of all B cell lymphoma <ref>{{Cite journal|last=Kuper-Hommel|first=Marion J. J.|last2=van de Schans|first2=Saskia A. M.|last3=Vreugdenhil|first3=Gerard|last4=van Krieken|first4=J. Han J. M.|last5=Coebergh|first5=Jan Willem W.|date=2013-09|title=Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites|url=https://pubmed.ncbi.nlm.nih.gov/23302044|journal=Leukemia & Lymphoma|volume=54|issue=9|pages=1891–1897|doi=10.3109/10428194.2013.764421|issn=1029-2403|pmid=23302044}}</ref>
**Group of Marginal zone lymphomas: [[Nodal Marginal Zone Lymphoma]], [[Splenic Marginal Zone Lymphoma]], MALT lymphoma
**Group of Marginal zone lymphomas: [[HAEM5:Nodal marginal zone lymphoma]], [[HAEM5:Splenic marginal zone lymphoma]], MALT lymphoma
*50% of primary gastric lymphoma <ref>{{Cite journal|last=Doglioni|first=C.|last2=Wotherspoon|first2=A. C.|last3=Moschini|first3=A.|last4=de Boni|first4=M.|last5=Isaacson|first5=P. G.|date=1992-04-04|title=High incidence of primary gastric lymphoma in northeastern Italy|url=https://pubmed.ncbi.nlm.nih.gov/1347858|journal=Lancet (London, England)|volume=339|issue=8797|pages=834–835|doi=10.1016/0140-6736(92)90280-g|issn=0140-6736|pmid=1347858}}</ref><ref>{{Cite journal|last=Isaacson|first=Peter G.|last2=Du|first2=Ming-Qing|date=2004-08|title=MALT lymphoma: from morphology to molecules|url=https://pubmed.ncbi.nlm.nih.gov/15286744|journal=Nature Reviews. Cancer|volume=4|issue=8|pages=644–653|doi=10.1038/nrc1409|issn=1474-175X|pmid=15286744}}</ref>
*50% of primary gastric lymphoma <ref>{{Cite journal|last=Doglioni|first=C.|last2=Wotherspoon|first2=A. C.|last3=Moschini|first3=A.|last4=de Boni|first4=M.|last5=Isaacson|first5=P. G.|date=1992-04-04|title=High incidence of primary gastric lymphoma in northeastern Italy|url=https://pubmed.ncbi.nlm.nih.gov/1347858|journal=Lancet (London, England)|volume=339|issue=8797|pages=834–835|doi=10.1016/0140-6736(92)90280-g|issn=0140-6736|pmid=1347858}}</ref><ref>{{Cite journal|last=Isaacson|first=Peter G.|last2=Du|first2=Ming-Qing|date=2004-08|title=MALT lymphoma: from morphology to molecules|url=https://pubmed.ncbi.nlm.nih.gov/15286744|journal=Nature Reviews. Cancer|volume=4|issue=8|pages=644–653|doi=10.1038/nrc1409|issn=1474-175X|pmid=15286744}}</ref>
*Median age 70<sup>th</sup> decade, F:M=1:1 with site specific sex differences; female predominance in thyroid and salivary glands <ref>{{Cite journal|date=1997-06-01|title=A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project|url=https://pubmed.ncbi.nlm.nih.gov/9166827|journal=Blood|volume=89|issue=11|pages=3909–3918|issn=0006-4971|pmid=9166827}}</ref>
*Median age 70<sup>th</sup> decade, F:M=1:1 with site specific sex differences; female predominance in thyroid and salivary glands <ref>{{Cite journal|date=1997-06-01|title=A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project|url=https://pubmed.ncbi.nlm.nih.gov/9166827|journal=Blood|volume=89|issue=11|pages=3909–3918|issn=0006-4971|pmid=9166827}}</ref>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":2">{{Cite journal|last=Troppan|first=Katharina|last2=Wenzl|first2=Kerstin|last3=Neumeister|first3=Peter|last4=Deutsch|first4=Alexander|date=2015|title=Molecular Pathogenesis of MALT Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/25922601|journal=Gastroenterology Research and Practice|volume=2015|pages=102656|doi=10.1155/2015/102656|issn=1687-6121|pmc=4397421|pmid=25922601}}</ref></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":2">{{Cite journal|last=Troppan|first=Katharina|last2=Wenzl|first2=Kerstin|last3=Neumeister|first3=Peter|last4=Deutsch|first4=Alexander|date=2015|title=Molecular Pathogenesis of MALT Lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/25922601|journal=Gastroenterology Research and Practice|volume=2015|pages=102656|doi=10.1155/2015/102656|issn=1687-6121|pmc=4397421|pmid=25922601}}</ref></blockquote>
</blockquote>
</blockquote>
==Individual Region Genomic Gain/Loss/LOH==
==Individual Region Genomic Gain / Loss / LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
|}
|}
<blockquote class='blockedit'>{{Box-round|title=v4:Individual Region Genomic Gain/Loss/LOH|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Individual Region Genomic Gain / Loss / LOH|The content below was from the previous version of the page. Please incorporate above.}}
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
|}
|}
==Gene Mutations (SNV/INDEL)==
==Gene Mutations (SNV / INDEL)==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV / INDEL)|The content below was from the previous version of the page. Please incorporate above.}}
==Links==
==Links==
[[Nodal Marginal Zone Lymphoma]]
[[HAEM5:Nodal marginal zone lymphoma]]
[[Splenic Marginal Zone Lymphoma]]
[[HAEM5:Splenic marginal zone lymphoma]]
==References==
==References==
<nowiki>*</nowiki>''Citation of this Page'': “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases E]]
<nowiki>*</nowiki>''Citation of this Page'': “Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue</nowiki>.
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases E]]